Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Open Access
- 19 October 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (39), 41692-41705
- https://doi.org/10.18632/oncotarget.6150
Abstract
Nrf2 is a key transcription factor for genes coding for antioxidants, detoxification enzymes, and multiple drug resistance and it also confers resistance to anticancer drugs. Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Luciferase reporter assays and real-time PCR analysis indicated that the Nrf2 promoter activity and its mRNA levels were markedly suppressed by wild-type p53, but not by mutant p53. Chromatin immunoprecipitation (ChIP) further confirmed that wild-type p53 binds at the p53 putative binding site to block Sp1 binding to the Nrf2 promoter and consequently to suppress the Nrf2 promoter activity. The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC.Keywords
This publication has 40 references indexed in Scilit:
- Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic FunctionsPLOS ONE, 2013
- Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung CancerPLOS ONE, 2013
- Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis*Journal of Biological Chemistry, 2012
- Somatic mutations of the KEAP1 gene in common solid cancersHistopathology, 2012
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant ResponseMolecular Cell, 2009
- The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative StressJournal of Biological Chemistry, 2009
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2Carcinogenesis: Integrative Cancer Research, 2008
- Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung CancerPLoS Medicine, 2006